Marine medicinal glycomics by Vitor H. Pomin
REVIEW ARTICLE
published: 29 January 2014
doi: 10.3389/fcimb.2014.00005
Marine medicinal glycomics
Vitor H. Pomin*
Program of Glycobiology, Institute of Medical Biochemistry Leopoldo de Meis, and University Hospital Clementino Fraga Filho, Federal University of Rio de Janeiro,
Rio de Janeiro, Brazil
Edited by:
Eliana Barreto-Bergter, Universidade
Federal do Rio de Janeiro, Brazil
Reviewed by:
Shu-Lin Liu, Harbin Medical
University, China
Margaret E. Bauer, Indiana
University School of Medicine, USA
*Correspondence:
Vitor H. Pomin, Program of
Glycobiology, Institute of Medical
Biochemistry Leopoldo de Meis,
and University Hospital Clementino
Fraga Filho, Federal University of Rio
de Janeiro, R. Prof. Rodolpho Paulo
Rocco, 255, HUCFF 4A01, Ilha do
Fundão, Rio de Janeiro,
RJ 21941-913, Brazil
e-mail: pominvh@bioqmed.ufrj.br
Glycomics is an international initiative aimed to understand the structure and function of
the glycans from a given type of cell, tissue, organism, kingdom or even environment, as
found under certain conditions. Glycomics is one of the latest areas of intense biological
research. Glycans of marine sources are unique in terms of structure and function. They
differ considerably from those of terrestrial origin. This review discusses the most known
marine glycans of potential therapeutic properties. They are chitin, chitosan, and sulfated
polysaccharides named glycosaminoglycans, sulfated fucans, and sulfated galactans. Their
medical actions are very broad. When certain structural requirements are found, these
glycans can exhibit beneficial effects in inflammation, coagulation, thrombosis, cancer
growth/metastasis, and vascular biology. Both structure and therapeutic mechanisms of
action of these marine glycans are discussed here in straight context with the current
glycomic age through a project suggestively named marine medicinal glycomics.
Keywords: carbohydrate-based drug development, chitin, chitosan, glycosaminoglycans, sulfated fucans, sulfated
galactans
INTRODUCTION
After the launch of many international biological ome initiatives,
the glycome has now emerged as a source of great information
(Hart and Copeland, 2010). Glycome is the project and glycomics
is the studies concerned with the science of carbohydrates or
glycobiology. Glycomics aims to describe systematically and com-
paratively the specific or general properties of the carbohydrates.
These carbohydrates may be within a repertoire of a given type
of cell, tissue, organism, kingdom, or a certain environment as
found under specific conditions. Glycomics is focused on the
studies and description of the structural and biological functions
of carbohydrates. The particular underlying mechanisms of sugar
biosynthesis, catabolism, and the nature of molecular interactions
with functional proteins involved in health and pathology are also
relevant topics of study in glycomics.
Glycomics has brought more challenges than other ome
projects. The reason is that carbohydrates are the utmost com-
plex biomolecules in terms of structure. High dynamic behavior,
Abbreviations: AMCase, acidic mammalian chitinase; aPTT, activated partial
thromboplastin time; AT, antithrombin; bFGF, basic fibroblast growth factor; BCT,
blood coagulation time; FGFR, fibroblast growth factor receptor; DS, dermatan
sulfate; Fucp, L-fucopyranose; FucCS, fucosylated chondroitin sulfate; GAGs,
glycosaminoglycans; GalNAc, N-acetyl D-galactosamine; Galp, galactopyranose;
GlcA, D-glucuronic acid; GlcN, D-glucosamine; GlcNAc, N-acetyl D-glucosamine;
GnT-V, N-acetylglucosaminyltransferase-V; HCII, heparin cofactor II; HMWC,
high molecular weight chitosans; ICAM, intercellular cellular adhesion molecule;
IdoA, L-iduronic acid; LMWC, low molecular weight chitosans; Man, mannose;
MMWC, medium molecular weight chitosans; MSPs, marine sulfated polysaccha-
rides; MW, molecular weight; PA, platelet aggregation; PRP, platelet-rich plasma;
PDGF-AB, platelet derived growth factor-AB; PSGL-1, P-selectin glycoprotein
ligand-1; RANTES, regulated on activation normal T-cell expressed and secreted;
SGs, sulfated galactans; SFs, sulfated fucans; SPs, sulfated polysaccharides; TGF-
β, transforming growth factor-β; VEGF, vascular endothelial growth factor; IIa,
thrombin; Xa, factor X activated; XIIa, factor XII activated.
conformational fluctuations, diversity of monomers, glycosidic
linkages, enantiomers, anomericity, extensive and inhomoge-
neous post-polymerization modifications are all relevant contrib-
utors to greatly enhance structural complexity in glycobiology.
Moreover, the number of carbohydrate classes is very high. They
include N-linked or O-linked oligosaccharides in glycoproteins,
glycosaminoglycans (GAGs) in proteoglycans, sulfated fucans
(SFs), sulfated galactans (SGs) and many others. Because of this,
glycomics is a sum of many individual subprojects rather than a
single and unique project. This helps to decrease the complexity
of the system. Based on this natural division new terminolo-
gies are being created to describe the subprojects. Some exam-
ples are sialome (for sialic acid-containing glycans) (Cohen and
Varki, 2010), glycosaminoglycanome (for GAGs) (Gesslbauer and
Kungl, 2006), heparanome (for heparan sulfate) (Lamanna et al.,
2007), proteoglycanome (for proteoglycans) (Gesslbauer et al.,
2007), fucanome (for SFs) (Pomin, 2012a,b), and galactanome
(for SGs) (Pomin, 2012a,b).
The most medically relevant functions of carbohydrates are
those related with clinical treatment (therapy) or prevention
(prophylaxis). These areas of glycobiology are boosted not only
to develop new health care products but due to the efforts of
multinational pharmaceutical companies to design and manu-
facture novel carbohydrate-based drugs. Although several glycans
have therapeutic properties those of marine origin have a special
position. This is particularly due to the unique structural fea-
tures that are not found in naturally occurring terrestrial sources.
The medicinal mechanisms of action of the marine glycans are
also quite distinct (Pomin and Mourão, 2008; Pomin, 2009).
Research using structurally well-defined glycans from marine
organisms helps to achieve accurate structure-function relation-
ships (Pomin, 2012b,c). Marine sources are rich in glycans of
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well-defined chemical structures that can be used to achieve these
accurate relationships, as discussed further. These accurate cor-
relations between structure and medical function are extremely
important for drug discovery and development, especially when
novel glycans are under investigation.
This document aims to describe, in a systematic way, the main
structural and medical properties of the most well known gly-
cans from the sea. These glycans are chitin, chitosan, and sulfated
polysaccharides (SPs), named GAGs, SFs, and SGs. When certain
structural features are present, these glycans can exhibit benefi-
cial activities in inflammation, coagulation, thrombosis, cancer,
and vascular biology. The underlying mechanism of actions for
their medical effects will be described here individually for each
class of marine polysaccharide. All the background provided
herein will be discussed in direct connection with glycomics. In
fact, this set of information strongly supports the incorpora-
tion and development of a new subproject in glycomics, which
is suggestively named marine medicinal glycomics. The objec-
tive of this subproject in the currently ongoing glycomic era
is not limited to dissemination of knowledge regarding thera-
peutic marine carbohydrates but meant to assist research pro-
grams focused on marine carbohydrate-based drug discovery and
development.
CHITIN AND CHITOSAN
Chitin is the second most abundant polysaccharide on earth after
cellulose. Cellulose is mostly terrestrial while chitin is marine
and terrestrial. In the marine environment, chitin is certainly
the most abundant biopolymer. Chitin is structurally composed
of 2-acetamino-D-glucose, also named N-acetyl D-glucosamine
(GlcNAc), and 2-amino-D-glucose also known as D-glucosamine
(GlcN) units. These units are linked by β(1→ 4) glycosidic
bonds (Figure 1A). In chitin the GlcNAc content is above 70%
of the total monosaccharide. This implies that this polysaccha-
ride is highly N-acetylated. This in turn significantly decreases its
hydrosolubility property. Low hydrosolubility levels give rise to
the main natural function of chitin, which is to create a protective
surface in invertebrate and fungal organisms. Themajor examples
are exoskeletons in arthropods, especially insects and arachnids,
shells in crustaceans and mollusks and cell walls in fungi.
The unique structure and particular physicochemical proper-
ties of chitin make this glycan very useful to industries of several
kinds. Chitin, its derivatives, and enzymes involved in their pro-
cessing are all globally explored by manufacturers of cosmetics
and food products. Chitin is also used by agricultural, pharma-
ceutical, and biomedical companies. However, the interest and
application in medicine clearly surpasses any other area (Sugano
et al., 1980; Suzuki et al., 1982; Nishimura et al., 1986; Bourbouze
et al., 1991; Fukada et al., 1991; Ikeda et al., 1993; Maezaki
et al., 1993; Deuchi et al., 1995; Bleau et al., 1999; Shibata et al.,
1997, 2000; Cho et al., 1998; Khor, 2001; Barone et al., 2003;
Okamoto et al., 2003; Qian and Glanville, 2005; Di Rosa et al.,
2005; Malaguarnera et al., 2005; Owens et al., 2006; Zhou et al.,
2006; Harish Prashanth and Tharanathan, 2007; Jayakumar et al.,
2007; Bonferoni et al., 2008; Liu et al., 2008; Wu et al., 2008; Yang
et al., 2008; Muzzarelli, 2009; Paolicelli et al., 2009; Perioli et al.,
2009; Tan et al., 2009).
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FIGURE 1 | 3D structural representation of the marine glycans (A)
chitin and chitosan, (B) ascidian dermatan sulfates (DSs), and (C)
sea-cucumber fucosylated chondroitin sulfate (FucCS). These pictures
represent the lowest-energy conformations obtained by computational
simulation on Chem3D Ultra 8.0 software using 10,000 step intervals of
2.0 fentosecond each, at 298K and heating/cooling rate of
1000Kcal/atom/ps. (A) Chitin and chitosan are composed of β-(1–4)-linked
D-glucosamine (GlcN) and N-acetyl D-glucosamine (GlcNAc) units with
different amounts. Chitin has ≥70% GlcNAc units while chitosan is
composed of ≤30% of this same unit. (B) The DS from ascidian Styela
plicata, Halocynthia pyriformis, and Phallusia nigra are composed of
[→4)-α-L-IdoA-(2R1,3R2)-(1→3)-β-D-GalNAc-(4R3, 6R4)-(1→]n with different
(Continued)
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FIGURE 1 | Continued
sulfation patterns (Pavão et al., 1995, 1998). S. plicata DS has R1, R2, R3,
and R4 at 66, <5, 94, 6%, respectively. H. pyriformis DS has R1, R2, R3,
and R4 at 70, <5, 99, 1%, respectively. P. nigra DS has R1, R2, R3, and R4
at 80, <5, <5, and 100%, respectively. (C) The FucCS from Ludwigothurea
grisea composed of {→4)-β-D-GlcA-3[→1)-α-L-Fucp-2,4-di(OSO−3 )]-
(1→3)-β-D-GalNAc-(1→]n (Vieira and Mourão, 1988; Vieira et al., 1991;
Mourão et al., 1996; Fonseca et al., 2010). IdoA, GalNAc, GlcA, and Fucp
stand for iduronic acid, N-acetyl galactosamine, glucuronic acid, and
fucopyranosyl units. Carbon (C), oxygen (O), hydrogen (H), sulfur (S) and
nitrogen (N) atoms are represented in gray, red, white, yellow, and blue,
and indicated by numbers within their positions in the sugar rings. The
unpaired electrons of oxygens and nitrogens are shown in pink. The OH
groups in (B) DS and (C) FucCS molecules that can be substituted by
sulfate ester groups are highlighted in bold for rapid visualization.
The structure of chitin polymers can be found at three forms,
α, β, and γ. The α-chitin is known to have a parallel-sheet con-
formation and is the most abundant form in nature. This form
can be found in the shells of crabs and shrimps. The β-chitin is
found in the spines of diatoms, squid pens, and pogonophoran
tubes. The β-chitin polymers are made of anti-parallel sheets. The
γ-chitin, which occurs in fungi and yeast, is comprised of both
α and β forms, thus, having a mixture of both anti-parallel and
parallel sheets.
Chitin, which has a compact conformation made of highly
acetylated regions and sheet-rich 3D-structures, is poorly water-
soluble. These properties make industrial and commercial explo-
ration of this structure difficult. To enhance hydrosolubility,
chemically modified or hydrolyzed derivatives are usually gener-
ated. For example, alkaline hydrolysis removes the acetyl groups
and leaves just the amino groups allowing the polymer to be
converted from a poorly water-soluble molecule into a highly
water-soluble one.
Chitosan is a cationic polysaccharide made up of the same
units and glycosidic linkage of chitin (Figure 1A). However, low
amounts of GlcNAc are found in chitosan, usually less than
30%. Physicochemical characteristics like hydrophobicity and
inter-chain interactions depend on the amount and distribu-
tion of acetyl groups. Another physicochemical characteristic that
varies naturally among different chitosan samples is themolecular
weight (MW). Based on this characteristic, three categories of chi-
tosan exist. These categories are named accordingly to their differ-
ent MWs: high molecular weight chitosans (HMWC), medium
molecular weight chitosans (MMWC), and low molecular weight
chitosans (LMWC). The MW ranges between 10–100 kDa for
LMWC, 100–300 kDa for MMWC, and over 300 kDa for HMWC.
In aqueous solution the HMWC sample are more viscous than
those prepared with LMWC or MMWC polymers. Although
LMWC can be obtained by size exclusion chromatography of
unmodified chitosans, enzymatic methods can be additionally
employed to produce LMWC derivatives. Although chitosan and
its derivatives are all cationic by nature, structural differences
among them account for differences in their biological activi-
ties and physicochemical properties (Zhang et al., 2009; Ozhan
Aytekin et al., 2012).
Chitin and chitosan are widely explored as dietary supple-
ments. Some pharmaceutical functions of chitin and chitosan
occur due to their unique physicochemical properties as natu-
rally occurring molecules. They are non-toxic, renewable, and
biodegradable. Depending on structures, they exert antitumor,
immunoenhancement, antimicrobial, and hypocholesterolemic
properties. These properties and activities make these polymers
very promising therapeutic candidates (Ilium, 1998). Other ther-
apeutic applications of chitin and chitosan are also under current
investigation. Examples are their multiple effects in drug deliv-
ery and gene therapy. These activities include ocular, nasal, and
vaginal delivery as well as targeted delivery into tumor sites,
colon, and wound dressing (bandages). These two marine car-
bohydrates have also the capability in interacting with receptors
on macrophage surfaces to stimulate an immune response in cells
(Muzzarelli, 2009) as detailed further. Other clinical effects are
also discussed below.
EFFECTS ON IMMUNE RESPONSE
It has been shown that chitin microparticles are effective in
clinical treatments including tumor cases, bacterial and viral
infections (Suzuki et al., 1982; Nishimura et al., 1986; Shibata
et al., 1997). Administration of these particles through the vas-
cular system enhances the generation and release of cytokines
by macrophages. The action of chemokines responsible to acti-
vate leukocytes in immunological events is mediated by various
surface receptors. These receptors act as agents that help internal-
ization of chitin microparticles. Because of the stimulatory action
on macrophages, it is believed that chitin plays a pivotal role in
depressing allergen-induced type 2 inflammatory responses. This
belief is supported by the fact that cytokines are involved in the
regulation of allergic immune responses (Shibata et al., 2000).
Moreover, it is also known that chitin is a T helper cell type 1
(Th1) adjuvant agent. It has the ability to up-regulate Th1 immu-
nity at the same time it down-regulates T helper cell type 2 (Th2)
immunity. The principal type of chitin with this property is the
shrimp α-chitin. Microparticles made of shrimp α-chitin have the
ability to convert an allergic response mediated by Th2 immu-
nity into an inflammatory response mediated by Th1 immunity
(Muzzarelli, 2009).
Studies in mammals have shown that in cases of infection,
chitinase enzymes can increase immunity (Bleau et al., 1999).
This finding was supported by trials on allergic and asthmatic
patients in which macrophages have shown increased expression
of acidic mammalian chitinase (AMCase) (Barone et al., 2003;
Di Rosa et al., 2005; Malaguarnera et al., 2005). Although some
researches of chitin-related enzymes has clearly pointed toward
beneficial properties in immunologic system, the specific roles of
such enzymes in host defense mechanisms as possible therapeutic
agents are yet to be uncovered.
IN FORMULATIONS FOR DRUG DELIVERY
In the recent years of the glycomics age, researches about drug
delivery and development has placed a great deal on chitosan due
to its capacity of addressing drugs to target tissues. This can be
done efficiently by different administration routes such as nasal,
oral, intra-peritoneal, and intravenous. Some outcomes provided
by these different routes of administration or targeted treatments
using chitosan molecules are shown in Table 1.
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Table 1 | Successful applications of chitin and chitosan in drug delivery.
Delivery systems Application References
Ocular delivery Ocular nanomedicines to be used in clinical practices from chitosan-based nanosystems Zhang et al., 2009
Nasal delivery Insulin transportation due to mucoadhesive, cationic and biodegradable properties of
PEG-g-chitosan nanoparticles
Paolicelli et al., 2009
Targeted delivery to tumors Reduction of systematic cytotoxicity, inhibition of cancer cell growth, induction of apoptosis of
bladder tumor cells
Tan et al., 2009
Vaginal delivery Mucoadhesion, enhanced penetration, peptidase inhibition by chitosan containing tablets Perioli et al., 2009
Wound dressing Healing of wounded soft tissue, bone, nerve, cartilage by chitin and chitosan based materials Bonferoni et al., 2008
HYPOCHOLESTEROLEMIC AND HYPOLIPIDEMIC PROPERTIES
As hypocholesterolemic and hypolipidemic agents, chitosan
molecules can lower the total cholesterol, plasma and liver
triacylglycerol levels quite effectively (Sugano et al., 1980; Fukada
et al., 1991; Ikeda et al., 1993; Maezaki et al., 1993; Cho et al.,
1998). These activities have been reported with little or no dras-
tic side effects. Chitosans of different MW exhibit distinct effects
(Maezaki et al., 1993). The varying activity was demonstrated
by in vitro studies using LMWC derivatives of different MW
ranges. Results have indicated that LMWC derivatives of different
MWs have different fat-binding and bile-salt-binding capacities
(Zhou et al., 2006; Liu et al., 2008). Another influencing fac-
tor in binding properties of chitosan fibers is the particle size of
LMWC derivatives. Powdered forms of chitosan have shown to
have higher binding capacities when compared to flake forms.
The hypocholesterolemic activity of LMWC derivatives may be
explained by electrostatic attraction and absorption mechanisms
with bile-salts and fatty acids. In the stomach, LMWC derivatives
entrap fat droplets when chitosan fibers and fat are consumed
together. This entrapment mechanism leads to precipitation of
the fat molecules together with LMWC derivatives, which leads
to formation of clusters at neutral pH in the small intestine. This
prevents fat digestion (Deuchi et al., 1995; Zhou et al., 2006). This
is a procedure widely explored by pharmaceutical industries to
develop dietary and health care chitosan-based products, mainly
used for weight control or reduction. Nevertheless, the ability to
reduce fat-absorption by LMWC fibers is likely to be significantly
lower or nonexistent if very acidic conditions are found in the
stomach.
EFFECTS ON HEMOSTASIS
Pure chitin/chitosan fibers have wound healing and blood coagu-
lating properties. They can be used either as internal hemostatic
dressing or as hemostatic bandages (Qian and Glanville, 2005;
Harish Prashanth and Tharanathan, 2007; Jayakumar et al., 2007;
Khor, 2001). Purity levels of this marine glycan are influen-
tial for these activities. This molecule is mostly obtained from
shells of marine organisms and, during isolation procedures,
other naturally occurring molecules can be co-extracted as con-
taminants. Studies have demonstrated that depending on the
dose and purity, both chitin and chitosan are significantly effec-
tive on decreasing the blood coagulation time (BCT) (Okamoto
et al., 2003). In this work, the effects of both chitin and chi-
tosan on blood coagulation and platelet aggregation (PA) were
evaluated using canine blood in in vitro experiments. Whole
blood was mixed with chitin and chitosan suspensions (0.0001–
1.0mg/ml), and then the BCT was measured. Chitin and chi-
tosan have been proven to reduce BCT in a dose-dependent
manner. Platelet-rich plasma (PRP) was mixed with chitin- and
chitosan-suspensions, and then PA was measured in a dual aggre-
gometer. The PA level induced by chitin was the strongest of
all samples tested including chitosan, cellulose and latex used
as comparative standards. When washed platelets were used,
the PA level induced by chitin was similar to that of chitosan,
while the rate of coagulation was lower than that of PRP. Chitin
and chitosan have shown the ability to enhance the release of
platelet derived growth factor-AB (PDGF-AB) and transform-
ing growth factor-β (TGF-β) from platelets (Okamoto et al.,
2003).
The hemostatic effect of chitosan as an internal dressing agent
against bleeding of liver, aorta, lung, kidney, and cardiac ven-
tricle wounds have been tested and certified by in vivo exper-
iments (Owens et al., 2006). Hemostatic property of chitosan
may benefit patients with coagulopathies since this therapeutic
property is independent of coagulation (co)factors (Yang et al.,
2008; Zhang et al., 2009). The beneficial activity of chitosan
depends almost entirely on platelets, as supported previously
(Okamoto et al., 2003; Wu et al., 2008). In vitro experiments
have proven that the hemostatic activity of chitosan can con-
tribute effectively to PA and adhesion (Zhang et al., 2009).
Therefore, serpin-dependent and -independent anticoagulant
and antithrombotic pathways are not involved in the effect of
chitosan.
EFFECTS AGAINST CANCER
Enzymes that are involved in chitin/chitosan synthesis and
degradation are generally named glycosyltransferases and glycosi-
dases, respectively. They are highly specific in terms of reaction.
In biosyntheses, for instance, the presence and amounts of the
correct substrate, sugar donors, and enzyme dictate whether the
reaction will occur or not. These enzymes have been noted to be
expressed in different levels accordingly to healthy or patholog-
ical conditions. The over- or down-expression of these enzymes
will result in significant changes of the structures of the cellular
glycans. Therefore, the structural integrity of the surface glycans
at the surface of healthy cells is intimately controlled by the activ-
ities of glycosyltransferases and glycosidades. A small change in
the balance of the activities of these two enzymes can lead to
diseases (Ohtsubo and Marth, 2006). Studies have demonstrated
that changed expressions of these enzymes are in fact indicators
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of carcinogenesis. For example, the β(1→ 6) branch levels of
N-linked glycans, found between mannose (Man) and GlcNAc
units are seen to be increased in tumor cases. Interestingly, these
units are products from digestions of chitin and chitosan polysac-
charides. More specifically, the structure GlcNAc-β(1→ 6)-Man-
α(1→ 6)Man-β results from a combination of available substrate
(the digested chitin/chitosan) and the specific glycosyltransferase,
N-acetylglucosaminyltransferase-V (GnT-V) (Humphries et al.,
1986; Fernandes et al., 1991; Handerson and Pawelek, 2003; Dube
and Bertozzi, 2005;Wattenberg, 2006). In vivo studies have shown
that β(1→ 6) GlcNAc branching, catalyzed by GnT-V activity,
is intimately related with carcinogenesis (Wattenberg, 2006). In
terms of therapy, the regulation of the up-take levels of chitin and
chitosan and the control of the enzyme activities related with the
degradation of these polymers, by gene and/or enzymatic therapy,
are effective clinical routes to decrease availability of substrates
used to build up glycans involved in tumor development.
In addition to what has been mentioned above, chitin syn-
thase and chitinase that work on synthesis and degradation of
chitin, respectively, have also shown to play a key role in inva-
sion by many pathogens, including tumor cells. Hence, inhibitors
of chitin synthases might have therapeutic uses in cancer. In fact,
several reports using in vitro and in vivo experiments have pointed
out that plant and bacterial chitinases are indeed effective agents
in cancer regressions (Pan et al., 2005; Sotgiu et al., 2008; Xu et al.,
2008).
SULFATED POLYSACCHARIDES
Marine GAGs have different structures than those present
in common mammal GAGs. For example, dermatan sulfate
(DS) isolated from the ascidian species Phallusia nigra is
composed of [→4)-α-L-IdoA-(2R1,3R2)-(1→3)-β-D-GalNAc-
(4R3,6R4)-(1→]n, where IdoA is iduronic acid, GalNAc is
N-acetyl galactosamine, R1, R2, R3, and R4 are sulfate groups
at 80, <5, <5, and 100 percent, respectively, (Figure 1B) (Pavão
et al., 1995). Conversely, the commonest mammalian DS ismostly
composed of 2-sulfated IdoA units together with occasional C4
sulfation at GalNAc units. Another different GAG from marine
invertebrates is fucosylated chondroitin sulfate (FucCS) isolated
from the sea-cucumber Ludwigothurea grisea, which is composed
of [→4)-β-D-GlcA-3[→1)-α-L-Fucp-2,4-di(OSO−3 )]-(1→3)-β-
D-GalNAc-(1→]n, in which GlcA is glucuronic acid, and Fucp
is a fucopyranosyl residue (Figure 1C) (Vieira and Mourão,
1988). Conversely, the commonest chondroitin sulfate (CS) in
mammals is composed of [→4)-β-D-GlcA-(1→3)-β-D-GalNAc-
(1→]n where its GalNAc units can be either mostly 4-sulfated
(CS-A) or predominantly 6-sulfated (CS-C) (Pomin et al., 2012).
As opposed to ascidian DS and sea-cucumber FucCS which are
heterogeneous marine sulfated polysaccharides (MSPs) in terms
of monosaccharide composition, the SFs and SGs are very homo-
geneous given that they are composed of only Fucp or galactopy-
ranose (Galp) units distributed in a quite regular and repeating
backbone (Table 2). The major differences between species from
SFs or SGs are either the sulfation pattern or the glycosidic linkage
type (Figure 2 and Table 2). From comparative studies using the
SFs and SGs shown in Table 2, their biomedical responses can be
understood based on some structural requirements (Pereira et al.,
2002). This analytical procedure helps to uncover the underlying
mechanisms of action of their biomedical effects through a very
accurate and efficient way. Some of the results in these advanced
structure-function relationship studies are detailed below.
Besides the unique structures of the MSPs, they also show
differential medical properties (Cumashi et al., 2007). This is
especially evident when compared to the common mammalian
SPs, GAGs. The medical properties of MSPs are directly related
to some of their unique structural features, which are not found
Table 2 | Oligosaccharide repetitive units of SFs and SGs from echinoderms sea-urchins (Echinoidea), and sea-cucumber (Holothuroidea), red
algae (Rhodophyta), and ascidians or tunicates (Ascidiacea).
Species (class) Structure
Ludwigothuria grisea (holothurioidea) [→3)-α-L-Fucp-2,4(OSO−3 )-(1→3)-α-L-Fucp-(1→3)-α-L-Fucp-2(OSO−3 )-(1→3)-α-L-Fucp-2(OSO−3 )-(1→]n
Strongylocentrotus purpuratus II (echinoidea) [→3)-α-L-Fucp-2,4di(OSO−3 )-(1→3)-α-L-Fucp-4(OSO−3 )-(1→3)-α-L-Fucp-4(OSO−3 )-(1→]n
Strongylocentrotus purpuratus I (echinoidea) 80% [→3)-α-L-Fucp-2,4di(OSO−3 )-(1→]n and 20% [→3)-α-L-Fucp-2(OSO−3 )-(1→]n
Strongylocentrotus franciscanus (echinoidea) [3)-α-L-Fucp-2(OSO−3 )-(1→]n
Strongylocentrotus droebachiensis (echinoidea) [→4)-α-L-Fucp-2(OSO−3 )-(1→]n
Strongylocentrotus pallidus (echinoidea) [→3)-α-L-Fucp-2(OSO−3 )-(1→3)-α-L-Fucp-2(OSO−3 )-(1→3)-α-L-Fucp-4(OSO−3 )-(1→3)-α-L-Fucp-4(OSO−3 )-
(1→]n
Lytechinus variegatus (echinoidea) [→3)-α-L-Fucp-2(OSO−3 )-(1→3)-α-L-Fucp-2(OSO−3 )-(1→3)-α-L-Fucp-4(OSO−3 )-(1→3)-α-L-Fucp-
2,4di(OSO−3 )-(1→]n
Arbacia lixula (echinoidea) [→4)-α-L-Fucp-2(OSO−3 )-(1→4)-α-L-Fucp-2(OSO−3 )-(1→4)-α-L-Fucp-(1→4)-α-L-Fucp-(1→]n
Echinometra lucunter (echinoidea) [→3)-α-L-Galp-2(OSO−3 )-(1→]n
Glyptosidaris crenularis (echinoidea) [→3)-β-D-Galp-2(OSO−3 )-(1→3)-β-D-Galp-(1→]n
Botryocladia occidentalis (rodophyta) [→3)-β-D-Galp-2R1-3R2-(1→4)-α-D-Galp-2R3-3R4-(1→]n, where R# = OSO−3 or OH, R1 and R2= OSO−3
in ∼66 and 33%, respectively
Gelidium crinale (rodophyta) [→3)-β-D-Galp-2R1-4R2-(1→4)-α-D-Galp-2R3-3R4-(1→]n, where R# = OSO−3 or OH, R1 and R2= OSO−3
in ∼60 and 15%, respectively
Styela plicata (ascidiacea) {→4)-α-L-Galp-2[→1)-α-L-Galp]-3(OSO−3 )-(1→}n
Hedmania monus (ascidiacea) [→4)-α-L-Galp-3(OSO−3 )-(1→]n
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FIGURE 2 | 3D structural representation of the sea-urchin 3-linked
2-sulfated glycans: (A) sulfated fucan (SF) from Strongylocentrotus
franciscanus, and (B) sulfated galactan (SG) from Echinometra
lucunter both shown at their tetrasaccharide models. These pictures
represent the lowest-energy conformations obtained by computational
simulation on Chem3D Ultra 8.0 software using 10,000 step intervals of 2.0
fentosecond each, at 298K and heating/cooling rate of 1000Kcal/atom/ps.
The polymers are made of the following structures (A)
[→3)-α-L-Fucp-2(OSO−3 )-(1→]n (Alves et al., 1997) for sea-urchin
S. franciscanus, and (B) [3)-α-L-Galp-2(OSO−3 )-(1→]n (Vilela-Silva et al., 1999)
for sea-urchin E. lucunter. Galp and Fucp stand for galactopyranosyl and
fucopyranosyl units, respectively. Carbon (C), oxygen (O), hydrogen (H), and
sulfur (S) atoms are represented in gray, red, white, and yellow. They have
not been indicated because of the big conformational overlap. The unpaired
electrons of oxygens are shown in pink.
in mammalian counterparts. For example, while the mammalian
CS, which lacks a fucosyl branch, is a non-anticoagulant polysac-
charide, the marine FucCS is anticoagulant since it naturally bears
the fucosyl branch (Mourão et al., 1996). If this branch is removed
in the MSP, for example, by mild acid hydrolysis, it becomes
inactive as anticoagulant (Mourão et al., 1996). Below, some of
these unique structural requirements necessary to achieve a good
response in the medical actions of the MSPs will be described.
This will be made through a systematic discussion about the
structure-function relationship in the medical activities of the
ascidian DS, sea-cucumber FucCS, sea-urchin and red algal SFs
and SGs whose mechanisms of action have been elucidated. The
events in which these mechanisms of action have been eluci-
dated are inflammation, coagulation, thrombosis, cancer, and
angiogenesis.
ANTI-INFLAMMATORY EFFECTS
When some structural requirements are present, theMSPs (ascid-
ian DS, sea-cucumber FucCS and sea-urchin or algal SFs and SGs)
may exhibit anti-inflammatory activities, as observed by in vitro
and in vivo experiments (Borsig et al., 2007; Cumashi et al., 2007;
Melo-Filho et al., 2010; Belmiro et al., 2011; Kozlowski et al., 2011;
Pomin, 2012b,c). The anti-inflammatory action of these MSPs
essentially resides in abrogating the P- and L-selectin-mediated
leukocyte trafficking, and recruitment and the chemokine-related
leukocyte activation during inflammatory events. Hypotheses
that the MSPs can also sequester chemokines also exist (Pomin,
2012b). Hence, the MSPs may exhibit anti-inflammatory activ-
ities via both cellular and molecular mechanisms of inflam-
mation. A detailed description of the mechanisms of action is
illustrated in Figure 3 for SFs and SGs used as examples. It
seems that the same mechanisms of action also occur for the
ascidian DS and the sea-cucumber FucCS (Borsig et al., 2007;
Melo-Filho et al., 2010; Belmiro et al., 2011; Kozlowski et al.,
2011).
As seen in most steroidal anti-inflammatory drugs, such as
the glucocorticoids, downside immunosuppressive effects for the
above-mentioned anti-inflammatory mechanisms of the MSPs
can exist. Since the extravasation of leukocytes to the sites
of infection are impaired by the use of MSPs in optimal
anti-inflammatory doses, the lower levels of leukocytes at the
infected or injured sites are somewhat disrupted. This can
decrease the ability of patients to fight infections.
The work of Melo-Filho and coworkers has shown that the
sea-cucumber FucCS can greatly attenuate progression of renal
fibrosis. This was observed using animals submitted to unilat-
eral ureteral obstruction. The anti-fibrotic mechanism occurs
through the stoppage of the P-selectin-driven cell migrations
(Melo-Filho et al., 2010). In this work essentially based on in vivo
experiments, mice were given 4mg/kg body weight of FucCS
intraperitoneally, once a day. After 14 days of injection, their
kidneys were examined by histological, immune-histochemical,
and biochemical methods. Compared with control mice, collagen
deposition decreased in the course of renal fibrosis in the mice
receiving FucCS as revealed by Sirius red staining and hydrox-
yproline content. The cellularity related to myofibroblasts and
macrophages was also clearly reduced, as was the production of
TGF-β. Fibrosis induced by unilateral ureteral obstruction was
observed markedly decreased in P-selectin-deficient mice, which
was also proved insensitive to the invertebrate GAG. In this ref-
erence, the authors have clearly demonstrated the attenuation
ability of FucCS in renal fibrosis using the ureteral obstruction
model in mice. As conclusion, the anti-inflammatory mechanism
in which FucCSworks is mostly driven by P-selectin-mediated cell
migration (Melo-Filho et al., 2010).
The phenomenon of P-selection blocking activity by FucCS
was demonstrated again in the work of Borsig and co-authors
(Borsig et al., 2007). In this work, the authors have shown by
in vitro experiments that not only heparin can block P- and
L-selection, but also the sea-cucumber FucCS. The blocking
action of these GAGs impairs the binding of selectins with
sialyl Lewis(x). This blocking action disrupts the rolling and
migration of the leukocytes on the vessel surfaces close to the
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FIGURE 3 | Simplified scheme regarding the inflammation mechanisms
in (A) normal (untreated) vs. (B) the treated condition with exogenous
sulfated fucans (SFs) and sulfated galactans (SGs). These glycans can
target multiple points during the inflammatory process. (A) In response to an
inflammatory stimuli, such as a bacterial infection, resident macrophages in
inner tissues produce both chemokines that attract more leukocytes into
these inflamed tissues, and cytokines (such as tumor necrosis factor, TNF)
that trigger, at the early stages, the display of pre-formed P-selectins on the
luminal surface of endothelial cells (the cytokine-induced P-selectin exposure
is not shown at the panels). Cytokines can also induce the expression of
E-selectin by endothelial cells (mechanism not shown). GAGs at endothelial
proteoglycans play an important role in L-selectin binding, in chemokine
presentation to chemokine receptors on neutrophils, and in the transportation
of chemokines produced by tissue macrophages and further infiltrated
leukocytes. Intercellular adhesion molecule (ICAM), and P-selectin
glycoprotein ligand-1 (PSGL) are important leukocyte cell-membrane proteins
involved in rolling and firm adhesion, respectively. (B) In the presence of SFs,
and likely SGs, by direct contact, both P- and L-selectins are blocked to
interact further with PSGL-1, and GAGs, respectively, thus, causing a
reduction on the leukocyte recruitment. In addition, at certain concentrations,
SFs and SGs sequestrate the chemokines responsible to drive and to activate
the leukocytes. This is another anti-inflammatory action of these marine
glycans. This sequestration occurs most likely because of the presence of
conserved heparin-binding sites (BBXB motifs, where B and X are basic and
neutral amino acids) in some pro-inflammatory chemokines such as
CCL5/RANTES. Due to chemokine sequestration, the numbers of activated
defense cells, their firm attachment to the endothelial surface and further
infiltration become all consequently reduced in treatment cases. Besides
those actions, the number of released chemokine as a pro-inflammatory
feedback process from inner tissues is also attenuated due to the decreased
number of infiltrated cells. This latter event enhances the anti-inflammatory
activity of the MSPs. All mechanisms marked by X in (B) collaborate in
conjunction to the resultant anti-inflammatory action of SFs and SGs. Figure
reproduced with permission from (Pomin, 2012b).
inflamed sites. The sea-cucumber FucCS was proven to be a
potent inhibitor of P- and L-selectin binding to immobilized
sialyl Lewis(x), and of LS180 carcinoma cell attachment to
immobilized P- and L-selectins. Inhibitions have been shown
to occur in a concentration-dependent manner. Interestingly,
FucCS was 4–8-fold more potent than heparin in the inhibi-
tion of P- and L-selectin-sialyl Lewis(x) interactions. No inhi-
bition of E-selectin was observed. This was expected based on
similar studies undertaken by Cumashi and coworkers on the
anti-inflammatory activity of some brown algal SFs (Cumashi
et al., 2007). In the work of Borsig et al. (2007), FucCS
demonstrated to have inhibitory properties on lung colonization
of adenocarcinoma MC-38 cells in an experimental metasta-
sis using mice. This inhibitory activity was also observed in
neutrophil recruitment in two in vivo models of inflamma-
tion (thioglycollate-induced peritonitis and lipopolysaccharide-
induced lung inflammation). Inhibition occurred at a dose that
produces no significant change in plasma activated partial throm-
boplastin time (aPTT). Removal of the sulfated fucose branches in
the FucCS (Figure 1C) abolished its inhibitory effect as observed
by both in vitro and in vivo experiments. This proves the impor-
tance for the fucosyl branch for this activity. The results from
this reference suggest that invertebrate FucCS may be a potential
alternative to heparin for blocking metastasis and inflammation
without the undesirable anticoagulant side effects seen in
heparin.
Another beneficial aspect of MSPs was shown in studies of the
anti-inflammatory potential of ascidian DS with different struc-
tures (Figure 1B) (Belmiro et al., 2011; Kozlowski et al., 2011).
Subcutaneous administration of ascidian DS has shown thera-
peutic effects against colon inflammation in rats by reducing
macrophage and T-cell recruitment and activation. These activ-
ities are in perfect coherence with the mechanisms described in
Figure 3. The work of Belmiro also showed the capacity of DS as
an anti-inflammatory agent in decreasing the myofibroblast pop-
ulation in fibrosis-induced mice submitted to unilateral ureteral
obstruction. The in vivo experiment used was similar to that used
in the work of Melo-Filho et al. (2010). In the work of Kozlowski,
the investigators showed in vivo anti-inflammatory action of two
ascidian DSs. The conclusion was based on the ascidian DS capac-
ity to block infiltration of defense cells in a thioglycollate-induced
peritonitis mouse experiment (Kozlowski et al., 2011).
Cumashi and coworkers have shown anti-inflammatory effects
of some brown algal SFs using in vitro assays to test the bind-
ing properties of the MSPs with selectins. Curiously, the brown
algal heterogenous SFs (also known as fucoidans) were able to
clear inhibit P- and L-selectins but not E-selectin (Cumashi et al.,
2007).
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ANTICOAGULATION AND ANTITHROMBOSIS: THE
SERPIN-INDEPENDENT MECHANISM
The effects of MSPs on hemostasis are the mostly studied med-
ical activities of these compounds. A detailed scheme describing
their major mechanism of action, as possible anticoagulants and
antithrombotics, is provided at Figure 4, in which SFs and SGs
are used as examples. The mechanisms of action reside on the
inhibition of some coagulation proteases like thrombin (IIa)
and factor Xa, via their physiological inhibitors, named serpins
(serine-protease inhibitors). The most common serpins of this
system are antithrombin (AT) and heparin cofactor II (HCII).
Although at different degrees of response, the majority of the
MSPs described herein: the ascidian DS (Figure 1B) (Vicente
et al., 2004; Kozlowski et al., 2011), the sea-cucumber FucCS
(Figure 1C) (Mourão et al., 1996; Mourão, 2004), the algal SFs
and SGs (Table 2) (Pereira et al., 1999; Farias et al., 2000; Mourão,
2004; Pomin and Mourão, 2012) and the invertebrate SFs or
SGs (Figure 2 and Table 2) (Pereira et al., 1999; Farias et al.,
FIGURE 4 | A few of the molecular and cellular players in (A) blood
coagulation, clot and thrombus formation; and (B) the anticoagulant
and antithrombotic mechanisms of the marine sulfated fucans (SFs)
and sulfated galactans (SGs). (A) When the blood vessel wall is
disrupted by an injury (atherosclerotic plaque or a physical rupture, for
example) tissue factors normally expressed and localized below the basal
lamina become exposed to the blood stream. Blood factor XII is
recognized by tissue factor, and after making complex with it, becomes
factor XII activated (XIIa) (complex not shown). XIIa initiates the blood
coagulation cascade leading to the expressive formation of thrombin (IIa)
and factor X activated (Xa). These factors feed the formation of more
blood coagulation factors which will result in clot or thrombus formation.
Thrombin acts directly on fibrinogen in order to form fibrin fibers, which
stabilizes the clots and thrombus through cross-linked fibers. Platelets play
an important role to this stabilization as well. The natural inhibitors of the
two proteases (Xa and IIa) are the serpins antithrombin (AT), and heparin
cofactor II (HCII). AT is able to act directly on either Xa or IIa, whereas
HCII acts only on IIa. Upon interaction with heparan sulfates and dermatan
sulfates of proteoglycans distributed throughout the endothelial surface of
blood vessels, AT and HCII become activated for inhibiting actions. This
leads to sequestration of the plasma soluble Xa and IIa factors. It is worth
to mention that AT is a heparin-binding protein with the BBXB motif of
high-affinity to SPs. HSPG and DSPG stand for heparan sulfate and
dermatan sulfate proteoglycans, respectively. (B) The inhibitory
mechanisms provoked by MSPs are analogous to the natural inhibitory
mechanisms caused by the proteoglycans at surfaces of the vessels.
However, due to the large plasmatic amounts of SFs and SGs in treatment
conditions, the cofactors AT and HCII would have their natural inhibitory
actions enhanced by certain orders of magnitude, consequently lowering
the plasmatic concentration of active factors IIa and Xa. The decreased
amounts of these blood factors abrogate the clotting and thrombus
formation, as a consequent result. Fibrinolytic activity is responsible to
undertake metabolic process on formed clots and thrombus after
significant inactivation of the proteases Xa and IIa. All the mechanisms
marked by X in (B) lead to the anticoagulant and antithrombotic actions of
SFs and SGs. Figure reproduced with permission from (Pomin, 2012b).
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2000; Pomin, 2012b), have all effects in this serpin-dependent
mechanism (Figure 4). The anticoagulant effects of the MSPs are
intimately dependent on some of their structural features. For
example, the SF from Strongylocentrotus franciscanus (Figure 2A
and Table 2) is not an anticoagulant polysaccharide while the
SG from Echinometra lucunter (Figure 2B and Table 2) is anti-
coagulant (Pereira et al., 2002). The only difference between
these two compounds is the monosaccharide type. The other fea-
tures C3-glycosydic linkage, 2-sulfation, L-enatiomericity, and α-
anomericity are equal (Figure 2). This single structural difference
is enough to make either an active or an inactive compound.
Besides the common serpin-dependent anticoagulant activ-
ity of the FucCS from the sea-cucumber L. grisea (Figure 1C),
and the SG from the red alga Botryocaldia occidentalis (Table 2),
these glycans have also shown serpin-independent anticoagulant
actions (Glauser et al., 2008, 2009). Initially, their anticoagulant
actions were essentially attributed by their capacity in potentiate
factors Xa and IIa inhibition via AT and HCII, as summarized in
Figure 4. Currently, the sea-cucumber FucCS and the red algal
SG are also known to inhibit the generation of factor Xa and
IIa by interfering in the formation of the blood cofactor com-
plexes at the surface of the cells. Factor Xa is activated mainly
by the intrinsic tenase complex, while IIa is converted from II
by the prothrombinase complex. FucCS and SG were shown the
ability to inhibit the activation of these tenase and prothrombi-
nase complexes (Glauser et al., 2008, 2009). The formation of
these complexes is a key step for the generation and amplifica-
tion of the coagulation cofactors. Besides this serpin-independent
mechanism, another novel mechanism is the inhibition of throm-
bosis by targeting tissue factor in combination with factor Xa,
as reported by the recent work of Zhao and coworkers using the
sea-cucumber FucCS (Zhao et al., 2013).
THERAPEUTIC EFFECTS AGAINST CANCER GROWTH ANDMETASTASIS
The effects of MSPs against cancer growth seem to be related
to the blocking of tumor angiogenesis that feeds the growth
of tumor cells (Pomin, 2012b), as illustrated in Figure 5. Like
some mammal GAGs, such as heparin, MSPs have shown the
capacity to bind growth factors such as basic fibroblast growth
factor (bFGF) and vascular endothelial growth factor (VEGF).
This binding will impair, respectively, the differentiation of meso-
dermal cells into angioblasts and angioblasts into endothelial
cells (Figure 5). These cellular differentiations are important to
the neovascularization process (Figure 5). Several articles have
demonstrated the capacity of MSPs in binding with these growth
factors (Tapon-Bretaudière et al., 2000, 2002; Cumashi et al.,
2007).
Besides interfering in tumor neovascularization, the MSPs
have also the capacity to inhibit, to some extent, the metastasis
of tumor cells. This action is driven by blocking the adhesion
capacity of the tumor cell onto the surface of the blood vessels
(Figure 5) (Croci et al., 2001; Borsig et al., 2007; Kozlowski et al.,
2011). This step is crucial for proper migration and invasion of
the primary and mature cancer cells toward new spots of growth
(metastasis). The mechanism of action of this tumor adhesion
inhibition by MSPs seems to be related to the blocking of P- and
L-selectins. This inhibitorymechanism is similar to that described
for the anti-inflammatory activities described above (Borsig et al.,
2007; Kozlowski et al., 2011). In the recent work of Zhao and
coworkers, the investigators have additionally demonstrated that
the sea-cucumber FucCS also inhibits metastasis by targeting the
nuclear factor-κB pathway in melanoma B16F10 cells (Zhao et al.,
2013).
OTHER ACTIVITIES
Besides coagulation, inflammation, and tumor angiogenesis, the
MSPs can also show therapeutic actions in other systems. They
can act like wound healing (O’Leary et al., 2004), oxidative-stress
(Dore et al., 2013), nociception (Rodrigues et al., 2012), and viral
infections (Ponce et al., 2003). In wound healing a combination
of chitosan-fucoidan hydrogels were created for therapeutic pur-
poses (Sezer et al., 2008). Nevertheless, the mechanisms of action
of MSPs in these systems are yet unclear. However, it is strongly
believed that for antiviral activity the MSPs might be impairing
the adhesion of the virus particle onto host cells since many virus
need the negatively charged polysaccharides on host cell surfaces
for attachment and invasion. The clinical systems just described
here comprise new research areas for MSPs in terms of studying
their underlying mechanisms of action and the structural features
necessary for the effectiveness.
REMARKED CONCLUSIONS
Here, we have made clear the clinical significance of MSPs. Chitin
and chitosan (Figure 1A) are likely the mostly abundant polysac-
charides from the marine environment. They can show beneficial
effects in immune response, against cancer, in hemostasis, as
hypocholesteromic and hypolipidemic agents besides exhibiting
capacity to enhance drug delivery. Even though they exhibit an
impressive range of therapeutic actions, chitin/chitosan fibers
have mostly been used in the pharmaceutical market as merely
dietary supplements for weight control. GAGs from marine
organisms are really distinct in terms of function and structure.
Two main examples are the ascidian DS with different patterns of
sulfation (Figure 1B) and the sea-cucumber FucCS (Figure 1C).
The latter differs considerably from the common CS due to the
presence of fucosyl branches. This branch is a structural require-
ment for the biomedical properties since when it is removed
the sea-cucumber SP losses its medical properties. As opposed
to CS, FucCS can be used as a potential anti-inflammatory and
anticoagulant agent. Both ascidian DS and FucCS have not been
employed in researches of clinical trials. They have been used
only in in vitro and in vivo studies. The in vivo experiments
have mostly used laboratory wild and mutant mice models. SFs
and SGs are other important classes of SPs found in the sea.
In invertebrates and in some red algae, these compounds may
exist with well-defined chemical structures (Table 2). The use of
these structurally well-defined glycans has helped the develop-
ment of drug discovery by achieving accurate structure-function
relationships. These unique glycans has also helped to understand
the underlying mechanisms of action involved in some clinical
effects of theMSPs. The clinical events withmechanisms of action
mostly elucidated so far are anti-inflammation, anticoagulation,
antithrombosis, and anti-tumor angiogenesis. Although brown
algae SFs, widely known as fucoidans, do not have well-defined
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FIGURE 5 | A simplified scheme of the major biochemical
mechanisms involved in tumor angiogenesis. Multiple points of
action are targeted by the SFs and SGs. For a new blood vessel to be
formed and to grow properly there should be a feeding of stimulatory
angiogenic factors such as angiogenin, VEGF, FGF, and TGF-β for
formation of the new vessels. The mesenchymal–epithelial transition
must also occur concomitantly to provide newly formed endothelial cell
to help the construction of the new blood ducts. In this event,
modulated also by FGF molecules, mesodermal cells undergo transition
until angioblasts which is the precursors of mature endothelial cells.
Under the influence of VEGF, newly formed endothelial cells will be
used for building the novel vessels (Lamalice et al., 2007).
Neovascularization is a fundamental process for cancer growth in
primary tumors as well as to feed the tumor growth at new metastatic
spots. SFs and SGs can inhibit the action of FGF and VEGF molecules
either at the endothelial cell differentiation as well as during the
feeding of the angiogenesis development. Interactions of SFs and SGs
with these factors as well as with their respective receptors have been
observed. Besides this neovascularization inhibitory function, SFs and
SGs were also reported to synergically reduced tumor spreading by
decreasing their cell-adhesion capacity (Croci et al., 2001) during the
tumor proliferation stage. All the mechanisms marked by X collaborate
in conjunction to the anti-angiogenic and/or antitumoral effects of SFs
and SGs. Figure reproduced with permission from (Pomin, 2012b).
chemical structures, they are the mostly used MSPs in research.
Like chitin and chitosan fibers, the brown algal SFs have been used
as dietary supplement products in the market. Clinical trials in
animals are likely to be unknown for themajority of theMSPs dis-
cussed here. The clinical tests available so far are just those found
in the referential works cited through this document.
MARINE MEDICIAL GLYCOMICS
This document has as its main objective the description of the
most important marine carbohydrates with therapeutic actions,
as well as their main structural and medical properties. These gly-
cans are really unique, and this uniqueness seems to be related to
the marine source. Glycomics, as an area of research, has grown
significantly over the last few years. Based on the discoveries
made with respect to therapeutic properties of marine glycans,
as discussed here, we want to propose to the major international
scientific societies involved with drug development, glycobiology,
and marine biology, a glycomics subproject namedmarine medic-
inal glycomics. The subproject marine medicinal glycomics would
be very useful to push forward the research programs involved
with marine carbohydrate-based drug development. Since clini-
cal tests using the marine glycans here discussed, especially those
of Table 2, are virtually inexistent, the implementation of this
subproject would support research programs of licensed clinical
trials using these sugars. The implementation of this subproject
would also enhance the medical contribution of carbohydrates
in the currently ongoing glycomic age. Not only chitin/chitosan,
invertebrate GAGs, SFs, and SGs would benefit from this subpro-
ject, but actually, any marine carbohydrate possessed of medical
properties. Certainly the number of marine carbohydrate-based
drugs would increase significantly with the implementation of
such subproject.
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